An interventional study of Methylene Blue Intervention Group and Normal Saline Control Group in Septic Shock, Methylene Blue and Sepsis, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-12-30.
Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to investigate whether methylene blue injection can safely and effectively improve the survival rate of patients with severe septic shock, shorten the duration of norepinephrine use, reduce the dosage of vasopressors, promptly correct hemodynamics, and improve tissue perfusion and organ function impairment.
Researchers will compare methylene blue to a placebo (a look-alike substance that contains no drug) to see if methylene blue works to treat severe septic shock.
Participants will:
Administer a loading dose of 2.5 mg/kg via micro-pump over 15 minutes, followed by a maintenance infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.25 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
Primary Study Endpoint
Secondary Study Endpoints
Record the following indicators before methylene blue intervention and at 24 hours, 72 hours, and 5 days after the intervention:
862 studies on the registry are indexed under Shock, Septic; 207 are open to participants now.
This study's planned enrollment of 488 is above the median of 80 across 530 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →First Affiliated Hospital of Zhejiang University is the lead sponsor of 256 studies on the registry; 140 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Methylene blue injection, 2.5 mg/kg loading dose over 15 minutes, followed by a continuous infusion of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first.
Drug: Methylene Blue Intervention Group
Normal saline solution, administered in the same manner and duration as the methylene blue intervention.
Drug: Normal Saline Control Group
In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
28-day survival rate of enrolled patients
Our primary endpoint is the 28-day survival rate of enrolled patients: All enrolled patients will be followed from the time of randomization until 28 days post-enrollment, recording the survival status on the 28th day after enrollment. If a patient dies within 28 days post-enrollment, the number of survival days will be recorded. Note: 1. Cases where the family requests discharge to home for end-of-life care and the patient subsequently dies will be counted as death cases. 2. Cases where the family requests discharge for non-medical reasons such as financial constraints and no further treatment is sought will be counted as dropout cases.
Time frame: 28-day
The duration and dosage of norepinephrine use
The duration of norepinephrine use：The time from the start of norepinephrine (NE) administration after sepsis diagnosis until its discontinuation. The definition of discontinuation: NE must be stopped for ≥2 hours; if NE is stopped for \<2 hours, it is not considered discontinued. If NE is re-administered after being stopped for more than 2 hours, it is still considered discontinued. The dosage of norepinephrine use：the total dose of NE used within 72 hours after the patient is enrolled in the study.
Time frame: 28-day
The duration of mechanical ventilation
The number of days without mechanical ventilation within 28 days post-enrollment. Note: Only full days without mechanical ventilation can be counted as one day.
Time frame: 28-day
The duration of ICU stay
ICU length of stay: the number of days in the ICU starting from the time of patient enrollment in the study. Note: Some patients may have multiple ICU admissions; only the ICU stay duration after the current enrollment is recorded.
Time frame: 28-day
The duration of overall hospital stay
The duration of overall hospital stay: the total number of days hospitalized starting from the time of patient enrollment in the study. Note: Days hospitalized prior to enrollment are not included.
Time frame: 28-day
The safety of methylene blue injection
We will record the complications due to the use of methylene blue, such as hemolysis: We will determine the presence of hemolysis by daily monitoring of urine color, red blood cells, hemoglobin count in complete blood count, and bilirubin levels in liver function tests. If the patient's urine turns dark brown (similar to soy sauce), accompanied by a decrease in hemoglobin and red blood cell count and a simultaneous increase in bilirubin, hemolysis will be considered.
Time frame: 28-day
Plan to share: No — You can explain the reason and contact the study initiator via email to request the data. The email address is:yuwenqiao1980@zju.edu.cn
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Zhejiang University